Abstract
BackgroundCD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have